抗マラリア薬市場- 世界の産業規模、シェア、動向、機会、予測：薬剤タイプ別、マラリアタイプ別、地域別セグメント、競合、2020年～2030年

抗マラリア薬の世界市場は、2024年には5億5,420万米ドルと評価され、2030年には7億1,104万米ドルに達し、CAGR 4.44％で成長すると予測されています。

サハラ以南のアフリカやアジアの一部地域ではマラリアが依然として流行しており、効果的な治療に対する需要は引き続き旺盛です。アルテミシニンを主成分とする併用療法（ACT）は、その有効性と標準治療プロトコールにおける確立された役割により、引き続き市場をリードしています。薬剤耐性マラリア株の増加への対処を目的とした研究開発への投資が増加していることも、市場をさらに牽引しています。有効性とアドヒアランスを高めるため、3剤併用療法、長時間作用型注射剤、小児用の改良型製剤などの技術革新が進められています。進歩が続く一方で、市場は耐性パターンの進化による持続的な課題に直面しており、新規治療アプローチの継続的な開発の必要性が浮き彫りになっています。

市場促進要因

ヘルスケア産業の成長

主な市場課題

医薬品供給の不安定性

主要市場動向

ハーブ療法と植物療法への注目の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の抗マラリア薬市場に与える影響

第5章 世界の抗マラリア薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤タイプ別（キニーネ、クロロキン、プログアニル、アモジアキン、メフロキン、ヒドロキシクロロキン、ピリメタミン、その他）
  • マラリアタイプ別（熱帯熱マラリア原虫、マラリア原虫、三日熱マラリア原虫、卵形マラリア原虫、ノウルシマラリア原虫）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の抗マラリア薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の抗マラリア薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の抗マラリア薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の抗マラリア薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの抗マラリア薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 世界の抗マラリア薬市場：SWOT分析

第15章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 競合情勢

• Cipla Ltd
• GlaxoSmithKline Plc
• Ipca Laboratories Ltd.
• Merck & Co., Inc
• Novartis AG
• Zydus Cadila
• Sun Pharmaceutical Industries Ltd.
• Strides Pharma Science Limited
• Glenmark Pharmaceuticals Ltd.
• Lincoln Pharmaceuticals Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global Antimalarial Drugs Market was valued at USD 554.20 million in 2024 and is projected to reach USD 711.04 million by 2030, growing at a CAGR of 4.44%. With malaria remaining prevalent in regions like sub-Saharan Africa and parts of Asia, demand for effective treatments remains robust. Artemisinin-based combination therapies (ACTs) continue to lead the market due to their efficacy and established role in standard treatment protocols. The market is being further driven by increased investment in research and development aimed at addressing the rise in drug-resistant malaria strains. Innovations such as triple combination therapies, long-acting injectables, and improved formulations for children are being pursued to enhance effectiveness and adherence. While advancements continue, the market faces persistent challenges from evolving resistance patterns, highlighting the need for ongoing development of novel treatment approaches.

Key Market Drivers

Growth in Healthcare Industry

The sustained expansion of the global healthcare industry-projected to surpass USD 4 trillion annually-is significantly bolstering the antimalarial drugs market. Pharmaceuticals and biotechnology contribute nearly USD 850 billion, supported by diagnostics and medical technology. In malaria-endemic regions such as Africa, Asia, and Latin America, increased public and private investment in healthcare infrastructure has enhanced access to diagnostics and treatments. This improved accessibility enables timely intervention, allowing for broader administration of antimalarial drugs and supporting continuous market growth.

Key Market Challenges

Inconsistency in Drug Supply

Supply inconsistency remains a major hurdle in the global antimalarial drugs market, especially in regions where malaria is most prevalent. Despite advancements in drug development and distribution frameworks, many affected areas still experience irregular access to essential medications. This issue is most acute in remote or low-income regions with fragile healthcare infrastructure. Key contributing factors include limited manufacturing capacity, inefficient procurement systems, and logistical obstacles that lead to delayed or insufficient supply. Seasonal fluctuations in malaria cases-often linked to monsoon or rainy seasons-further strain these underprepared supply chains. Inadequate inventory control and fragmented distribution networks can result in stockouts at critical points of care, ultimately disrupting treatment and increasing health risks.

Key Market Trends

Increased Focus on Herbal and Plant-Based Therapies

There is a growing trend toward the development and adoption of herbal and plant-based therapies in the antimalarial drugs market. Plant-derived compounds such as quinine, quinidine, and artemisinin remain pivotal in the fight against malaria. This shift is largely influenced by rising interest in natural and traditional treatments, particularly in regions where indigenous medicine is widely practiced. Concerns regarding side effects of synthetic drugs and the emergence of resistant malaria strains have prompted researchers and pharmaceutical firms to explore botanical alternatives. Artemisinin-extracted from sweet wormwood-serves as a cornerstone of ACTs and exemplifies the clinical success of plant-based remedies. Ongoing exploration of other medicinal plants, including neem and cinchona bark, continues to expand the pipeline of potential antimalarial agents derived from natural sources.

Key Market Players

• Cipla Ltd
• GlaxoSmithKline Plc
• Ipca Laboratories Ltd.
• Merck & Co., Inc
• Novartis AG
• Zydus Cadila
• Sun Pharmaceutical Industries Ltd.
• Strides Pharma Science Limited
• Glenmark Pharmaceuticals Ltd.
• Lincoln Pharmaceuticals Ltd.

Report Scope

In this report, the Global Antimalarial Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antimalarial Drugs Market, By Drug Type:

• Quinine
• Chloroquine
• Proguanil
• Amodiaquine
• Mefloquine
• Hydroxychloroquine
• Pyrimethamine
• Others

Antimalarial Drugs Market, By Malaria Type:

• Plasmodium Falciparum
• Plasmodium Malariae
• Plasmodium Vivax
• Plasmodium Ovale
• Plasmodium Knowlesi

Antimalarial Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antimalarial Drugs Market.

Available Customizations

Global Antimalarial Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Antimalarial Drugs Market

5. Global Antimalarial Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Quinine, Chloroquine, Proguanil, Amodiaquine, Mefloquine, Hydroxychloroquine, Pyrimethamine, Others)
  • 5.2.2. By Malaria Type (Plasmodium Falciparum, Plasmodium Malariae, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Knowlesi)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Antimalarial Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Malaria Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antimalarial Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Malaria Type
  • 6.3.2. Mexico Antimalarial Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Malaria Type
  • 6.3.3. Canada Antimalarial Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Malaria Type

7. Europe Antimalarial Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Malaria Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Antimalarial Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Malaria Type
  • 7.3.2. Germany Antimalarial Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Malaria Type
  • 7.3.3. United Kingdom Antimalarial Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Malaria Type
  • 7.3.4. Italy Antimalarial Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Malaria Type
  • 7.3.5. Spain Antimalarial Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Malaria Type

8. Asia Pacific Antimalarial Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Malaria Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antimalarial Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Malaria Type
  • 8.3.2. India Antimalarial Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Malaria Type
  • 8.3.3. South Korea Antimalarial Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Malaria Type
  • 8.3.4. Japan Antimalarial Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Malaria Type
  • 8.3.5. Australia Antimalarial Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Malaria Type

9. South America Antimalarial Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Malaria Type
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Antimalarial Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Malaria Type
  • 9.3.2. Argentina Antimalarial Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Malaria Type
  • 9.3.3. Colombia Antimalarial Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Malaria Type

10. Middle East and Africa Antimalarial Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Malaria Type
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Antimalarial Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Malaria Type
  • 10.3.2. Saudi Arabia Antimalarial Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Malaria Type
  • 10.3.3. UAE Antimalarial Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Malaria Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Antimalarial Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Cipla Ltd
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. GlaxoSmithKline Plc
• 16.3. Ipca Laboratories Ltd.
• 16.4. Merck & Co., Inc
• 16.5. Novartis AG
• 16.6. Zydus Cadila
• 16.7. Sun Pharmaceutical Industries Ltd.
• 16.8. Strides Pharma Science Limited
• 16.9. Glenmark Pharmaceuticals Ltd.
• 16.10. Lincoln Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer